Pfizer's Prevenar-13 approved in the EU
This article was originally published in Scrip
Executive Summary
Pfizer's 13-valent pneumococcal vaccine Prevenar-13 has received an EU approval for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from six weeks to five years of age.